United Kingdom Patient-derived Xenograft Model Market Insight
The United Kingdom Patient-derived Xenograft Model Market is growing at an 9.6% CAGR, driven by rising oncology drug discovery demand, expansion of precision medicine research, increasing adoption of preclinical cancer models, and growing use of PDX platforms by pharmaceutical companies and CROs to improve translational research success and therapeutic development outcomes.
United Kingdom Patient-derived Xenograft Model Market Insights Forecasts to 2035
- The United Kingdom Patient-derived Xenograft Model Market Size Was Estimated at USD 362.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 9.6% from 2025 to 2035
- The United Kingdom Patient-derived Xenograft Model Market Size is Expected to Reach USD 906.4 Million by 2035
Notable Insights for United Kingdom Patient-derived Xenograft Model Market
- By application, oncology drug discovery dominated, accounting for approximately 55–60% share in 2024, driven by increasing cancer research programs and targeted therapy development.
- By cancer type, breast cancer and lung cancer models collectively held approximately 45–50% share, supported by high incidence rates and strong research focus in the UK.
- Around 60–65% of pharmaceutical and biotech oncology pipelines in the UK utilize PDX models during preclinical testing to improve predictive accuracy for human clinical response.
- Approximately 40–45% of PDX model demand comes from CROs and academic research institutes, reflecting growing outsourcing of complex in-vivo oncology studies.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Patient-derived Xenograft Model Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Patient-derived Xenograft Model Market
- Charles River Laboratories
- Champions Oncology
- The Jackson Laboratory
- Horizon Discovery (PerkinElmer)
- Crown Bioscience (JSR Life Sciences)
- WuXi AppTec
- Pharmatest Services
- XenoSTART
- Others
Recent Developments:
- In April 2025, Humanized PDX models are advancing UK oncology research by enabling immuno-oncology drug testing through mice engrafted with human immune cells, improving translational accuracy and cancer therapy evaluation.
- In March 2025, Recent studies highlight PDX models in colorectal cancer research to assess tumor heterogeneity and drug resistance, improving translational accuracy over cell lines in oncology drug development and precision medicine approaches.
Market Segmentation:
United Kingdom Patient-derived Xenograft Model Market, By Application
- Oncology Drug Discovery
- Precision Medicine Research
- Biomarker Development
- Others
United Kingdom Patient-derived Xenograft Model Market, By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
United Kingdom Patient-derived Xenograft Model Market, By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
United Kingdom Patient-derived Xenograft Model Market, By Model Type
- Mouse Models
- Rat Models
- Humanized Models
Expert Views:
The UK Patient-derived Xenograft Model Market is expected to expand steadily due to increasing reliance on translational oncology research and precision medicine initiatives. Experts emphasize that PDX models are becoming critical in predicting clinical drug responses, especially in immuno-oncology and targeted therapies. Growing collaboration between pharmaceutical companies and CROs is accelerating model adoption. Advances in humanized mouse systems and tumor biobanking are further enhancing research accuracy. Over the forecast period, integration with genomic profiling and AI-driven drug discovery is expected to significantly transform market dynamics.